Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...

Two undergraduate medicine students at University of Galway have led a major study examining how cardioprotective ...

The Trump administration recently nixed a rule proposed by President Biden that would have made it easier for 7.4 million ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

As demand soared for weight-loss drugs, price signals worked.

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The weight-loss drug revolution has arrived, and the food & beverage industry has begun to evolve in response to suppressed ...